Allozymes applies its patented microfluidics technology to accelerate custom biocatalysts discovery and optimization. The company combines its ultra-high throughput screening capability of 10 million assays a day with a proprietary enzyme database and machine learning models to develop highly selective enzymes for diverse chemistry and active pharmaceutical ingredient (API) manufacturing, ensuring intellectual property freedom to operate. Allozymes supports its clients by delivering accelerated proof-of-concepts, custom biocatalysts, and bioprocess development, with in-house capabilities to transition from lab to pilot scale and commercial production in collaboration with a global partner network.

Services include:
– APIs (Active Pharmaceutical Ingredients)
– Biologics
– Custom biocatalysts development
– Bioprocess development
– High-throughput screening

Allozymes stands out in the pharmaceutical industry by utilising advanced technology to streamline the development of biocatalysts and related processes. To find more information, please visit allozymes.com.